Your session is about to expire
← Back to Search
Long-term Niraparib for Cancer
Study Summary
This trial is for people who are already taking niraparib in other trials and want to keep taking it. The goal is to learn more about the long-term safety of the drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 37 Patients • NCT03207347Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently seeing positive results from my niraparib treatment.I am currently on niraparib treatment in a GlaxoSmithKline/TESARO study.I was taken off niraparib treatment for any reason.You are willing and able to comply with study procedures.I had to stop taking niraparib due to side effects, but I'm ready to resume once they're resolved.
- Group 1: Participants receiving niraparib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is recruitment still ongoing for this research endeavor?
"This study is no longer seeking patients. First published on April 16th 2021 and last updated July 20 2022, this trial has reached its recruitment limit. However, there are 4994 clinical trials available for those with breast cancer and 99 studies employing Niraparib currently accepting enrollees."
To what extent is Niraparib an issue of potential hazard?
"Niraparib's safety has been assessed at level 2 due to the limited clinical data available, as we are currently in phase 2 of this trial and efficacy is yet to be determined."
Does this experimental trial represent a pioneering effort in its field?
"Since 2016, researchers have been investigating the potential of Niraparib. In that same year Myriad Genetics Inc. launched a Phase 1 trial with 733 participants which eventually led to full drug approval for this medication in the third stage of clinical trials. As we speak, there are 99 active experiments employing Niraparib taking place around the globe spanning 49 nations and 485 cities."
How many volunteers have signed up to participate in this trial?
"At the present moment, this clinical trial is not seeking new participants. It was first made available on April 16th 2021 and last altered on July 20th 2022. However, if you are looking for other trials related to breast cancer there presently 4944 studies that need volunteers; 99 of them being Niraparib-related."
How widespread is the availability of this clinical trial?
"Currently, the medical trial is open for enrollment in 14 sites across North America. Tucson, Montreal and Vancouver are some of these locales with several more located close to you; therefore it's pertinent to pick a place that'll reduce transport needs if one decides to participate."
Are there any additional investigations that have utilized Niraparib?
"Currently, there are 99 Niraparib-related studies in progress. Of these medical investigations, 13 have advanced to phase 3 trials. The majority of the research is conducted in Washington District of Columbia but a total of 2816 sites are involved with this treatment's evaluation."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger